Genentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting

Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q

Needham & Company reiterated a Buy rating on Rogers Corp (NYSE: ROG), and raised the price target to $75.00 (from $70.00), following the company's 3Q earnings report. ROG reported revenues of $165M and EPS of $0.95, above prior guidance for $150-160M and adjusted EPS of $0.69-0.79. Previous consensus... More

Genentech (RHHBY) to Make 60+ Presentations at ASH 2016; Will Include Phase III GALLIUM Study Data

Genentech, a member of the Roche Group (OTC: RHHBY), announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting from December 3-6 in San Diego. The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.

The breadth of data we are presenting at ASH this year reflects our deep commitment to people with blood diseases, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. We are... More

Rogers (ROG) Tops Q3 EPS by 20c

Rogers (NYSE: ROG) reported Q3 EPS of $0.88, $0.20 better than the analyst estimate of $0.68. Revenue for the quarter came in at $165.3 million versus the consensus estimate of $154.02 million.

For earnings history and earnings-related data on Rogers (ROG) click here.